VIROLOGICAL RESPONSE AND TOLERANCE TO BOCEPREVIR OR TELAPREVIR PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN TRIPLE THERAPY IN HIV-HCV CO-INFECTED PATIENTS: REAL-LIFE FINDINGS FROM THE PAN STUDY

被引：0
|
作者：
Baumgarten, A. [1 ]
Holm, S. [2 ]
Lutz, T. [3 ]
Schranz, D. [4 ]
Mauss, S. [5 ]
Hillenbrand, H. [6 ]
Moll, A. [7 ]
Scholten, S. [8 ]
Schmidt, W. [9 ]
Goelz, J. [10 ]
Hintsche, B. [11 ]
Schleehauf, D. [10 ]
Fenske, S. [12 ]
Stephan, C. [13 ]
Prziwara, D. [14 ]
Koeppe, S.
Alshuth, U. [15 ]
Jaeger, H. [16 ]
机构：
[1] Mib Dienstleistung GmbH, Berlin, Germany
[2] Private Practice Dres Kuhlmann Holm Heiken, Hannover, Germany
[3] Infektiologikum, Frankfurt, Germany
[4] Private Practice Dres Schranz Fischer, Berlin, Germany
[5] Ctr HIV & Hepatogastroenterol, Dusseldorf, Germany
[6] Ctr Med, City Ost, Germany
[7] Ctr HIV & Hepatol, Berlin, Germany
[8] Ctr Med Hohenstaufenring, Cologne, Germany
[9] Praxiszentrum Kaiserdamm, MVZ Aerzteforum Seestrasse, Berlin, Germany
[10] Praxiszentrum Kaiserdamm, Ctr Addict Med Hepatol & HIV, Berlin, Germany
[11] Ctr Infectiol & Hepatol, Berlin, Germany
[12] ICH Grindelpraxis, Infekt Epidemiol Ctr, Hamburg, Germany
[13] JW Goethe Univ Hosp, Dept Infect Dis, Frankfurt, Germany
[14] Praxisteam Mitte, Berlin, Germany
[15] Roche Pharma AG, Virol, Grenzach Wyhlen, Germany
[16] MVZ Karlsplatz, HIV Res & Clin Care Ctr, Munich, Germany
来源：
JOURNAL OF HEPATOLOGY | 2014年 / 60卷 / 01期
关键词：
D O I：
10.1016/S0168-8278(14)61306-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1146
引用
收藏
页码：S464 / S464
页数：1
相关论文
共 50 条
  • [1] Virological response and tolerance of triple therapy including Telaprevir or Boceprevir in HIV-HCV co-infected cirrhotic patients: real-life early findings from the prospective ANRS CO13 HEPAVIH cohort
    Miailhes, Patrick
    Rosenthal, Eric
    Dominguez, Stephanie
    Morlat, Philippe
    Dupon, Michel
    Valantin, Marc-Antoine
    Gilbert, Camille
    Winnock, Maria
    Salmon, Dominique
    Sogni, Philippe
    HEPATOLOGY, 2013, 58 : 1167A - 1167A
  • [2] ACCESS TO HCV TRIPLE THERAPY WITH TELAPREVIR OR BOCEPREVIR WITH PEGINTERFERON RIBAVIRIN IN REAL LIFE SETTING IN HIV-HCV CO-INFECTED PATIENTS - ANRS CO13 Hepavih COHORT
    Poizot-Martin, I.
    Merchadou, L.
    Carrieri, P.
    Miailhes, P.
    Domingues, S.
    Dabis, F.
    Sogni, P.
    Loko, M. -A.
    Salmon, D.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S494 - S494
  • [3] SUSTAINED VIROLOGICAL RESPONSE (SVR) IN HCV TREATMENT-EXPERIENCED PATIENTS AFTER TRIPLE THERAPY WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN IN A REAL-LIFE SETTING
    Boeker, K. H. W.
    Link, R.
    Baumgarten, A.
    Stoehr, A.
    Heyne, R.
    Roessle, M.
    Schott, E.
    Ullrich, R.
    Erren, P.
    Herold, C.
    Schmidt, W.
    Simon, K. -G.
    Geissler, M.
    Schiffelholz, W.
    Alshuth, U.
    Hueppe, D.
    Mauss, S.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S462 - S463
  • [4] Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: SVR24 Final Study Results
    Sulkowski, Mark S.
    Sherman, Kenneth E.
    Soriano, Vincent
    Rockstroh, Juergen
    Dieterich, Douglas T.
    Girard, Pierre-Marie
    Bsharat, Mohammad
    Henshaw, Joshua
    Rubin, Raymond A.
    Garg, Varun
    Adda, Nathalie
    HEPATOLOGY, 2012, 56 : 219A - 219A
  • [5] Safety and efficacy of triple therapy containing boceprevir (BOC) or telaprevir (TVR) plus peginterferon alfa-2a / ribavirin in patients with advanced fibrosis or cirrhosis in real-life setting
    Mauss, Stefan
    Schober, Andreas
    John, Christine
    Lutz, Thomas
    Moog, Gero
    Bruch, Harald-Robert
    Teuber, Gerlinde
    Christensen, Stefan
    Heyne, Renate
    Pape, Stefan
    Naumann, Uwe
    Roessle, Martin
    Schiffelholz, Willi
    Loehr, Hanns-Friedrich F.
    Alshuth, Ulrich
    Hueppe, Dietrich
    HEPATOLOGY, 2013, 58 : 1098A - 1099A
  • [6] PHYSICIAN ADHERENCE TO AND EFFICACY OF TRIPLE THERAPY WITH TELAPREVIR (TVR) PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN (PEGIFN/RBV) IN A REAL-LIFE SETTING
    Mauss, S.
    Schober, A.
    John, C.
    Lutz, T.
    Moog, G.
    Bruch, H. R.
    Teuber, G.
    Christensen, S.
    Heyne, R.
    Pape, S.
    Naumann, U.
    Roessle, M.
    Schiffelholz, W.
    Loehr, H.
    Alshuth, U.
    Hueppe, D.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S465 - S466
  • [7] TRIPLE THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN IN A REAL-LIFE SETTING: IS IT POSSIBLE TO ACHIEVE SVR RATES COMPARABLE TO PIVOTAL TRIALS?
    Buggisch, P.
    Schober, A.
    Bruch, H. R.
    Antoni, C.
    Loehr, H.
    Herrmann, A.
    Steffens, H.
    Moog, G.
    Haessner, J.
    Hoerster, H. -G.
    John, C.
    Schlueter, H. -J.
    Link, R.
    Heyne, R.
    Spengler, U.
    Alshuth, U.
    Hueppe, D.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S460 - S461
  • [8] Cost-effectiveness of peginterferon alfa-2b plus ribavirin for chronic hepatitis C in HIV-HCV co-infected patients
    Wong, JB
    Buti, M
    Casado, MA
    Fosbrook, L
    Soriano, V
    Esteban, R
    HEPATOLOGY, 2005, 42 (04) : 651A - 652A
  • [9] The Dose-Response Relationship of Peginterferon Alfa-2a and Ribavirin in the Treatment of Patients Coinfected with HIV-HCV
    Opravil, Milos
    Rodriguez-Torres, Maribel
    Rockstroh, Juergen
    Snoeck, Eric
    Chung, Raymond T.
    Tietz, Andreas
    Torriani, Francesca J.
    HIV CLINICAL TRIALS, 2012, 13 (01): : 33 - 45
  • [10] Peginterferon alfa-2a Plus Ribavirin for HIV-HCV Genotype 1 Coinfected Patients: A Randomized International Trial
    Rodriguez-Torres, Maribel
    Slim, Jihad
    Bhatti, Laveeza
    Sterling, Richard
    Sulkowski, Mark
    Hassanein, Tarek
    Serrao, Rosario
    Sola, Ricard
    Bertasso, Anne
    Passe, Sharon
    Stancic, Saray
    HIV CLINICAL TRIALS, 2012, 13 (03): : 142 - 152
12345